{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=42", "query": { "intervention": "pembrolizumab", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 1847, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:35:33.270Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03093428", "title": "Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Radium-223", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2017-06-09", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093428" }, { "nct_id": "NCT05027633", "title": "Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma", "the Nasal Cavity", "Paranasal Sinuses" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-11-02", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027633" }, { "nct_id": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "canakinumab", "type": "DRUG" }, { "name": "canakinumab-matching placebo", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 673, "start_date": "2018-12-21", "completion_date": "2026-01-26", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 4, "location_summary": "Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631199" }, { "nct_id": "NCT05518032", "title": "Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma", "Recurrent Colorectal Carcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Autologous Dendritic Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-10-01", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05518032" }, { "nct_id": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Ovarian Cancer", "Gastric Cancer", "Palpable Subcutaneous Malignant Lesions", "Renal Cell Carcinoma", "Melanoma", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Imiquimod Cream", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2019-04-26", "completion_date": "2026-07-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872947" }, { "nct_id": "NCT02981914", "title": "Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Classical Hodgkin Lymphoma", "B-cell Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-03-07", "completion_date": "2020-11-01", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981914" }, { "nct_id": "NCT03332498", "title": "Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Cancer", "Colorectal Cancer", "Colorectal Carcinoma", "Colon Disease" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-01-24", "completion_date": "2021-09-09", "has_results": true, "last_update_posted_date": "2022-06-03", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332498" }, { "nct_id": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "SEphB4-HSA", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vasgene Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2025-03-15", "completion_date": "2034-08", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06493552" }, { "nct_id": "NCT04696055", "title": "Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2021-02-03", "completion_date": "2024-04-23", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 9, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696055" }, { "nct_id": "NCT03123055", "title": "A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Urothelial Cell Carcinoma", "Urinary Bladder Disease", "Urological Diseases" ], "interventions": [ { "name": "B-701", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rainier Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-04-20", "completion_date": "2019-12-01", "has_results": true, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-10-31T12:35:33.270Z", "location_count": 8, "location_summary": "Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03123055" } ] }